Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Krystal Biotech, Inc. (KRYS : NSDQ)
 
 • Company Description   
Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

Number of Employees: 295

 
 • Price / Volume Information   
Yesterday's Closing Price: $335.19 Daily Weekly Monthly
20 Day Moving Average: 585,251 shares
Shares Outstanding: 29.48 (millions)
Market Capitalization: $9,881.40 (millions)
Beta: 0.50
52 Week High: $382.54
52 Week Low: $130.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.87% -7.56%
12 Week 27.81% 24.31%
Year To Date 35.96% 22.75%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2100 WHARTON STREET SUITE 701
-
PITTSBURGH,PA 15203
USA		 ph: 412-586-5830
fax: -		 investors@krystalbio.com http://www.krystalbio.com
 
 • General Corporate Information   
Officers
Krish S. Krishnan - Chief Executive Officer; President and Director
Suma M. Krishnan - President
Kathryn A. Romano - Chief Accounting Officer
Daniel S. Janney - Director
Julian Gangolli - Director

Peer Information
Krystal Biotech, Inc. (CORR.)
Krystal Biotech, Inc. (RSPI)
Krystal Biotech, Inc. (CGXP)
Krystal Biotech, Inc. (BGEN)
Krystal Biotech, Inc. (GTBP)
Krystal Biotech, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 501147102
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/03/26
Share - Related Items
Shares Outstanding: 29.48
Most Recent Split Date: (:1)
Beta: 0.50
Market Capitalization: $9,881.40 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $1.89 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $7.31 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 45.85
Trailing 12 Months: 44.81
PEG Ratio: -
Price Ratios
Price/Book: 7.74
Price/Cash Flow: 45.98
Price / Sales: 23.68
EPS Growth
vs. Year Ago Period: 52.50%
vs. Previous Quarter: 7.65%
Sales Growth
vs. Year Ago Period: 31.95%
vs. Previous Quarter: 8.64%
ROE
06/30/26 - -
03/31/26 - 19.25
12/31/25 - 18.69
ROA
06/30/26 - -
03/31/26 - 17.62
12/31/25 - 17.12
Current Ratio
06/30/26 - -
03/31/26 - 9.46
12/31/25 - 9.95
Quick Ratio
06/30/26 - -
03/31/26 - 9.06
12/31/25 - 9.56
Operating Margin
06/30/26 - -
03/31/26 - 53.92
12/31/25 - 52.64
Net Margin
06/30/26 - -
03/31/26 - 53.92
12/31/25 - 52.64
Pre-Tax Margin
06/30/26 - -
03/31/26 - 49.68
12/31/25 - 48.69
Book Value
06/30/26 - -
03/31/26 - 43.31
12/31/25 - 42.06
Inventory Turnover
06/30/26 - -
03/31/26 - 0.64
12/31/25 - 0.66
Debt-to-Equity
06/30/26 - -
03/31/26 - 0.00
12/31/25 - 0.00
Debt-to-Capital
06/30/26 - -
03/31/26 - 0.00
12/31/25 - 0.00
 

Powered by Zacks Investment Research ©